Your browser doesn't support javascript.
loading
Influence of Clinical and Surgical Factors on Uterine Carcinosarcoma Survival.
Gracia, Myriam; Yildirim, Yusuf; Macuks, Ronalds; Mancari, Rosanna; Achimas-Cadariu, Patriciu; Polterauer, Stephan; Iacoponi, Sara; Zapardiel, Ignacio.
Afiliación
  • Gracia M; Gynecologic Oncology Unit, La Paz University Hospital, Paseo de la Castellana 261, 28046 Madrid, Spain.
  • Yildirim Y; Tepecik Training and Research Hospital, Izmir 35020, Turkey.
  • Macuks R; Latvian Oncology Center, Riga Eastern Clinical University Hospital, LV-1079 Riga, Latvia.
  • Mancari R; Division of Gynecologic Oncology, European Institute of Oncology, IRCCS, 20139 Milan, Italy.
  • Achimas-Cadariu P; Gynecologic Oncology Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
  • Polterauer S; Prof Dr Ion Chiricuta Cluj-Napoca, University of Medicine and Pharmacy Iuliu Hatieganu, 400337 Cluj-Napoca, Romania.
  • Iacoponi S; Department of Obstetrics and Gynecology, Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria.
  • Zapardiel I; Gynecologic Oncology Unit, La Paz University Hospital, Paseo de la Castellana 261, 28046 Madrid, Spain.
Cancers (Basel) ; 15(5)2023 Feb 25.
Article en En | MEDLINE | ID: mdl-36900255
ABSTRACT

BACKGROUND:

The aim of this study was to assess the impact of prognostic factors on the survival of patients diagnosed with uterine carcinosarcoma.

METHODS:

A sub-analysis of the SARCUT study, a multicentric retrospective European study, was carried out. We selected 283 cases of diagnosed uterine carcinosarcoma for the present study. Prognosis factors influencing survival were analyzed.

RESULTS:

Significant prognostic factors for overall survival were incomplete cytoreduction (HR = 4.02; 95%CI = 2.68-6.18), FIGO stages III and IV (HR = 3.21; 95%CI = 1.83-5.61), tumor persistence after any treatment (HR = 2.90; 95%CI = 1.97-4.27), presence of extrauterine disease (HR = 2.62; 95%CI = 1.75-3.92), a positive resection margin (HR = 1.56; 95%CI = 1.05-2.34), age (HR = 1.02; 95%CI = 1.00-1.05), and tumor size (HR = 1.01; 95%CI = 1.00-1.01). Significant prognostic factors for disease-free survival were incomplete cytoreduction (HR = 3.00; 95%CI = 1.67-5.37), tumor persistence after any treatment (HR = 2.64; 95%CI = 1.81-3.86), FIGO stages III and IV (HR = 2.33; 95%CI = 1.59-3.41), presence of extrauterine disease (HR = 2.13; 95%CI = 1.44-3.17), administration of adjuvant chemotherapy (HR = 1.84; 95%CI = 1.27-2.67), a positive resection margin (HR = 1.65; 95%CI = 1.11-2.44), presence of LVSI (HR = 1.61; 95%CI = 1.02-2.55), and tumor size (HR = 1.00; 95%CI = 1.00-1.01).

CONCLUSIONS:

Incomplete cytoreduction, presence of tumor residual after treatment, advanced FIGO stage, extrauterine disease, and tumor size are significant prognostic factors decreasing disease-free survival and overall survival of patients with uterine carcinosarcoma.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article País de afiliación: España